GlaxoSmithKline (GSK) has reported positive results from the Phase III PETIT2 study evaluating the efficacy of eltrombopag vs placebo in paediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP).

Ninety three subjects at 38 centres in 14 countries were enrolled in PETIT2, a two-part, double-blind, randomised placebo-controlled and open-label trial.

In the trial, eltrombopag met its primary endpoint, achieving a statistically significant improvement in platelet counts with almost 40% of patients treated with eltrombopag attaining a consistent platelet response for six of eight weeks compared with placebo.

The trial’s primary objective was to evaluate the efficacy of eltrombopag, relative to placebo, in achieving platelet counts of =50 Gi/L among paediatric patients with previously treated cITP for at least 12 months.

Eltrombopag is marketed as Promacta in the US and as Revolade in Europe, as well as other countries worldwide.

GlaxoSmithKline head of oncology R&D Rafael Amado said: "We look forward to continuing to assess the potential of eltrombopag in these patients and to moving forward with planned regulatory submissions for a paediatric indication in cITP later this year."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, efficacy results for the trial were consistent across age cohorts, while the safety profile was consistent with the established profile for eltrombopag and no new safety concerns were observed.

Most common adverse events (AEs) occurring most frequently in the eltrombopag arm included nasopharyngitis, rhinitis, cough and respiratory tract infection.

The company said that grade 3/4 AEs occurred in 12.7% of patients treated with eltrombopag and 10.3% of patients in the placebo group, while serious AEs were reported in 8% of eltrombopag-treated patients vs 14% in the placebo arm.

Image: Petechiae, or small bruise-like markings, may occur in ITP. Photo: courtesy of Stevenfruitsmaak.